The UK private GP EHR (electronic health records) market is poised to grow due to a rising demand for private GP services, technological advancements, and the need to comply with regulations such as GDPR and CQC. However, privacy concerns and technical glitches might act as growth inhibitors. Private GP services are becoming more popular due to a drop in NHS GPs and a lack of primary physicians.
Startup OMass Secures $310M to Advance Drug for Rare Endocrine Disorder
OMass’s molecule is vying to become an alternative to a Neurocrine Biosciences drug that is currently the only FDA-approved therapy for congenital adrenal hyperplasia. But
